404 related articles for article (PubMed ID: 34206607)
1. Immunoproteasome Function in Normal and Malignant Hematopoiesis.
Tubío-Santamaría N; Ebstein F; Heidel FH; Krüger E
Cells; 2021 Jun; 10(7):. PubMed ID: 34206607
[TBL] [Abstract][Full Text] [Related]
2. The immunoproteasome as a target in hematologic malignancies.
Kuhn DJ; Orlowski RZ
Semin Hematol; 2012 Jul; 49(3):258-62. PubMed ID: 22726549
[TBL] [Abstract][Full Text] [Related]
3. The immunoproteasome as a therapeutic target for hematological malignancies.
Miller Z; Lee W; Kim KB
Curr Cancer Drug Targets; 2014; 14(6):537-48. PubMed ID: 25059201
[TBL] [Abstract][Full Text] [Related]
4. Targeting the ubiquitin proteasome system in haematological malignancies.
Crawford LJ; Irvine AE
Blood Rev; 2013 Nov; 27(6):297-304. PubMed ID: 24183816
[TBL] [Abstract][Full Text] [Related]
5. Immunoproteasome-selective and non-selective inhibitors: A promising approach for the treatment of multiple myeloma.
Ettari R; Zappalà M; Grasso S; Musolino C; Innao V; Allegra A
Pharmacol Ther; 2018 Feb; 182():176-192. PubMed ID: 28911826
[TBL] [Abstract][Full Text] [Related]
6. Inhibitors of the immunoproteasome: current status and future directions.
Miller Z; Ao L; Kim KB; Lee W
Curr Pharm Des; 2013; 19(22):4140-51. PubMed ID: 23181576
[TBL] [Abstract][Full Text] [Related]
7. Immunoproteasome-selective inhibitors: An overview of recent developments as potential drugs for hematologic malignancies and autoimmune diseases.
Xi J; Zhuang R; Kong L; He R; Zhu H; Zhang J
Eur J Med Chem; 2019 Nov; 182():111646. PubMed ID: 31521028
[TBL] [Abstract][Full Text] [Related]
8. Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance.
Narayanan S; Cai CY; Assaraf YG; Guo HQ; Cui Q; Wei L; Huang JJ; Ashby CR; Chen ZS
Drug Resist Updat; 2020 Jan; 48():100663. PubMed ID: 31785545
[TBL] [Abstract][Full Text] [Related]
9. Fragment-Sized and Bidentate (Immuno)Proteasome Inhibitors Derived from Cysteine and Threonine Targeting Warheads.
Kollár L; Gobec M; Proj M; Smrdel L; Knez D; Imre T; Gömöry Á; Petri L; Ábrányi-Balogh P; Csányi D; Ferenczy GG; Gobec S; Sosič I; Keserű GM
Cells; 2021 Dec; 10(12):. PubMed ID: 34943940
[TBL] [Abstract][Full Text] [Related]
10. Immunoproteasome-Selective Inhibitors: A Promising Strategy to Treat Hematologic Malignancies, Autoimmune and Inflammatory Diseases.
Ettari R; Previti S; Bitto A; Grasso S; Zappalà M
Curr Med Chem; 2016; 23(12):1217-38. PubMed ID: 26965184
[TBL] [Abstract][Full Text] [Related]
11. Immunoproteasome Activity in Chronic Lymphocytic Leukemia as a Target of the Immunoproteasome-Selective Inhibitors.
Besse A; Kraus M; Mendez-Lopez M; Maurits E; Overkleeft HS; Driessen C; Besse L
Cells; 2022 Mar; 11(5):. PubMed ID: 35269460
[TBL] [Abstract][Full Text] [Related]
12. The Functional and Mechanistic Roles of Immunoproteasome Subunits in Cancer.
Tripathi SC; Vedpathak D; Ostrin EJ
Cells; 2021 Dec; 10(12):. PubMed ID: 34944095
[TBL] [Abstract][Full Text] [Related]
13. Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines.
Niewerth D; Kaspers GJ; Assaraf YG; van Meerloo J; Kirk CJ; Anderl J; Blank JL; van de Ven PM; Zweegman S; Jansen G; Cloos J
J Hematol Oncol; 2014 Jan; 7():7. PubMed ID: 24418325
[TBL] [Abstract][Full Text] [Related]
14. Selective immunoproteasome inhibitors with non-peptide scaffolds identified from structure-based virtual screening.
Kasam V; Lee NR; Kim KB; Zhan CG
Bioorg Med Chem Lett; 2014 Aug; 24(15):3614-7. PubMed ID: 24913713
[TBL] [Abstract][Full Text] [Related]
15. Discovery and Early Clinical Development of Selective Immunoproteasome Inhibitors.
Kirk CJ; Muchamuel T; Wang J; Fan RA
Cells; 2021 Dec; 11(1):. PubMed ID: 35011570
[TBL] [Abstract][Full Text] [Related]
16. Ubiquitin-proteasome system as a target for anticancer treatment-an update.
Kim YJ; Lee Y; Shin H; Hwang S; Park J; Song EJ
Arch Pharm Res; 2023 Jul; 46(7):573-597. PubMed ID: 37541992
[TBL] [Abstract][Full Text] [Related]
17. On the role of the immunoproteasome in transplant rejection.
Basler M; Li J; Groettrup M
Immunogenetics; 2019 Mar; 71(3):263-271. PubMed ID: 30220008
[TBL] [Abstract][Full Text] [Related]
18. [The proteasome - structural aspects and inhibitors: a second life for a validated drug target].
Reboud-Ravaux M
Biol Aujourdhui; 2021; 215(1-2):1-23. PubMed ID: 34397372
[TBL] [Abstract][Full Text] [Related]
19. The immunoproteasome: a novel drug target for autoimmune diseases.
Basler M; Mundt S; Bitzer A; Schmidt C; Groettrup M
Clin Exp Rheumatol; 2015; 33(4 Suppl 92):S74-9. PubMed ID: 26458097
[TBL] [Abstract][Full Text] [Related]
20. On the Role of the Immunoproteasome in Protein Homeostasis.
Basler M; Groettrup M
Cells; 2021 Nov; 10(11):. PubMed ID: 34831438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
